HomeCompareSPGZ vs JNJ

SPGZ vs JNJ: Dividend Comparison 2026

SPGZ yields 0.01% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.6K in total portfolio value· pulled ahead in Year 4
10 years
SPGZ
SPGZ
● Live price
0.01%
Share price
$21,500.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.93
Full SPGZ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SPGZ vs JNJ

📍 JNJ pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPGZJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPGZ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPGZ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPGZ
Annual income on $10K today (after 15% tax)
$0.79/yr
After 10yr DRIP, annual income (after tax)
$0.79/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPGZ + JNJ for your $10,000?

SPGZ: 50%JNJ: 50%
100% JNJ50/50100% SPGZ
Portfolio after 10yr
$25.0K
Annual income
$2,345.17/yr
Blended yield
9.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPGZ
No analyst data
Altman Z
20.1
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPGZ buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPGZJNJ
Forward yield0.01%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$19.7K$30.3K
Annual income after 10y$0.93$4,689.40
Total dividends collected$9.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPGZ vs JNJ ($10,000, DRIP)

YearSPGZ PortfolioSPGZ Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,701$0.93$10,592$272.30+$109.00SPGZ
2$11,451$0.93$11,289$357.73+$162.00SPGZ
3$12,253$0.93$12,123$472.89+$130.00SPGZ
4← crossover$13,112$0.93$13,141$629.86$29.00JNJ
5$14,031$0.93$14,408$846.81$377.00JNJ
6$15,014$0.93$16,021$1,151.60$1.0KJNJ
7$16,066$0.93$18,122$1,588.22$2.1KJNJ
8$17,191$0.93$20,930$2,228.20$3.7KJNJ
9$18,396$0.93$24,792$3,191.91$6.4KJNJ
10$19,684$0.93$30,274$4,689.40$10.6KJNJ

SPGZ vs JNJ: Complete Analysis 2026

SPGZStock

Spectrum Group International, Inc., together with its subsidiaries, operates as a trading and collectibles network in the United States and Europe. The company operates in two segments, Trading and Collectibles. The Trading segment is engaged in the trade of metals, including gold, silver, platinum, and palladium for storage and delivery in the form of coins, bars, wafers, and grain; and providing financing, consignment, hedging, and various customized financial programs. This segment also offers loans on precious metals and rare coins collateral to coin dealers, collectors, and investors; promotes A-Mark bullion products; and offers storage solutions to institutions, dealers, and consumers. Its customers include sovereign mints and mines, manufacturers and fabricators, refiners, coin and bullion dealers, banks and other financial institutions, commodity brokerage houses, industrial users of precious metals, jewelers, private investors, investment advisors, and collectors. The Collectibles segment offers coins, paper currency, and rare and fine vintage wines. This segment sells its products to collectors and dealers through traditional live auctions, Internet and telephone auctions, and retail sale. The company was founded in 1981 and is headquartered in Irvine, California.

Full SPGZ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SPGZ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPGZ vs SCHDSPGZ vs JEPISPGZ vs OSPGZ vs KOSPGZ vs MAINSPGZ vs ABBVSPGZ vs MRKSPGZ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.